

**From:** Liverpool-ECMC  
**Sent:** 06 January 2020 08:20  
**To:** Liverpool-ECMC  
**Subject:** Liverpool ECMC Newsletter January 2020 - Solids

**Follow Up Flag:** Follow up  
**Flag Status:** Completed

## LIVERPOOL ECMC NEWSLETTER JANUARY 2020



### NEW EARLY PHASE TRIALS OPEN

The following trials are now open for recruitment:

**GO40987** - A phase I, multicentre, open-label pre-operative, short-term window study of GDC-9545 in postmenopausal women with stage I-III operable, **estrogen receptor-positive breast cancer**.

**QED BGJ398** - A phase II multicentre, single arm study of oral BGJ398 in adult patients with **advanced or metastatic cholangiocarcinoma** with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy.

**National Lung Matrix Trial** - Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in **non-small cell lung cancer (NSCLC)**.

Patients can be referred via [ccf-tr.ecmcreferrals@nhs.net](mailto:ccf-tr.ecmcreferrals@nhs.net).

## LIVERPOOL ECMC EARLY PHASE TRIALS CLINIC IS OPEN



The ECMC Early Phase Trials Clinic is now open. This weekly clinic runs every Monday afternoon at the Clatterbridge Cancer Centre.

Patients who are potentially eligible and interested in participating in phase I and non-randomised phase II clinical trials can be referred to this clinic via the following email address: [ccf-tr.ecmcreferrals@nhs.net](mailto:ccf-tr.ecmcreferrals@nhs.net).

## OPEN TRIALS

Please contact [Jennie Derham](#) for potential referral to these trials.

- Telephone: 0151 556 5443
- Mobile: 07554 416 293
- E-mail: [ccf-tr.ecmcreferrals@nhs.net](mailto:ccf-tr.ecmcreferrals@nhs.net)



## ADVANCED SOLID TUMOURS

- **ACIT-1** – A Phase I clinical study to determine the optimal dose for the safe immune restoration and immune response of allogeneic cell immunotherapy (ACIT-1) in adult cancer patients – *All advanced solid tumours*.
- **REPLIMUNE RP1** – An Open-Label, Multicenter, Phase 2 Study of RPI in Combination with Nivolumab in Patients with Microsatellite Instability High or Mismatch Repair Deficient Tumors – *Melanoma, Non-Melanoma Skin Cancer, Urothelial Bladder Carcinoma*.

- **REPLIMUNE RP2** – An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination with PD1 Blockade in Patients *with Solid Tumors*

## BREAST

- **CT7001 001** – A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies– *Advanced breast cancer.*
- **GO40987** – A Phase I, Multicenter, Open-Label Preoperative, Short-Term Window Study of GDC-9545 in Postmenopausal Women with *Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer*
- **plasmaMATCH** – A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening – *Advanced breast cancer.*

## HEAD & NECK

- **Cambridge Brain Mets Trial 1** – A proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy – *Brain metastases from lung or breast primary.*
- **NICO** – Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in oral cavity cancer – *squamous cell carcinoma of the oral cavity.*

## HPB / UPPER GI

- **OUTREACH** – A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (OUTREACH) – *Advanced liver cancer.*
- **POLARIS** - Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma - *Hepatocellular Carcinoma*
- **QED BGJ398** - A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy- *Cholangiocarcinoma*

## LUNG

- **National Lung Matrix Trial** – Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer.

## MELANOMA

- **Circulating Tumour DNA gUided therapy Switch (CACTUS)** – A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumour DNA in guiding a switch between targeted therapy and immune therapy in patients with *advanced cutaneous melanoma*.

## NON-CTIMPS

- **HYST** – Hypersensitivity Study: A Mechanistic Investigation into Drug and Chemical Induced Hypersensitivity Reactions
- **PRIMM** – Predicting Response to Immunotherapy for Melanoma with gut Microbiome and metabolomics (the PRIMM study)
- **PROACT** – Patient Reported Opinions About Clinical Tolerability
- **SMP-2** – The Cancer Research UK Stratified Medicine Programme: Pilot Study

**[Find out more...](#)**



**COMING SOON...**

The **LECMC Biomarker Discovery Programme** (sample collection study) is soon to open the Pancreas cohort at CCC.

All patients with suspected or actual diagnosed Pancreatic Ductal Carcinoma (PDAC), and those individuals who are undergoing or have been treated for PDAC in the past are potentially eligible for this study.

Please contact [ccf-tr.ecmcreferrals@nhs.net](mailto:ccf-tr.ecmcreferrals@nhs.net) for more information.

## EVENTS & JOB OPPORTUNITIES

### EVENTS

- [ECMC Junior Investigator Network Group: Training the Next Generation \(FEBRUARY 2020\)](#)
- <https://www.ecmcnetwork.org.uk/events>

## CONTACT US

If you require any information which isn't on the newsletter please contact the Liverpool ECMC Team via [e-mail](#).

*Copyright © 2019 Liverpool ECMC, All rights reserved.*

**Our mailing address is:**

[livecmc@liv.ac.uk](mailto:livecmc@liv.ac.uk)